Changes in the population structure of invasive neisseria meningitidis in the United States after quadrivalent meningococcal conjugate vaccine licensure

Journal of Infectious Diseases

Volumn 211, Issue 12, 2015, Pages 1887-1894

  Wang, Xin ^a   Shutt, Kathleen A ^b   Vuong, Jeni T ^a   Cohn, Amanda ^a   MacNeil, Jessica ^a   Schmink, Susanna ^a   Plikaytis, Brian ^a   Messonnier, Nancy E ^a   Harrison, Lee H ^b   Clark, Thomas A ^a   Mayer, Leonard W ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

meningococcal disease; molecular epidemiology; vaccine impact

Indexed keywords

ENTEROCHELIN; MENINGOCOCCUS VACCINE; PORIN A; VACCINE;

ARTICLE; BACTERIAL GENE; BACTERIAL GENETICS; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG RESPONSE; FETA GENE; GENE DELETION; GENETIC VARIABILITY; GENOTYPE; HORIZONTAL GENE TRANSFER; NEISSERIA MENINGITIDIS; NONHUMAN; POPULATION STRUCTURE; PORA GENE; PRIORITY JOURNAL; SEROTYPE; UNITED STATES; ADOLESCENT; ADULT; AGED; CHILD; CLASSIFICATION; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; INFANT; ISOLATION AND PURIFICATION; MALE; MENINGOCOCCAL INFECTIONS; MICROBIOLOGY; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; GENOTYPE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MIDDLE AGED; NEISSERIA MENINGITIDIS; SEROGROUP; UNITED STATES; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84930345695     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu842     Document Type: Article

References (30)

1. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010; 50:184-91.
2. Practices CfDCaPACoI. Revised recommendations of the Advisory Committee on Immunization Practices to Vaccinate all Persons Aged 11-18 Years with Meningococcal Conjugate Vaccine. Morb Mortal Wkly Rep 2007; 56:794-5.
3. Practices CfDCaPACoI. National and State Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2011. Morb Mortal Wkly Rep 2011; 61:671-7.
4. Granoff DM. Review of meningococcal group B vaccines. Clin Infect Dis 2010; 50(suppl 2):S54-65.
5. Lipsitch M, O'Hagan JJ. Patterns of antigenic diversity and the mechanisms that maintain them. J R Soc Interface 2007; 4:787-802.
6. Gupta S, Maiden MC, Feavers IM, Nee S, May RM, Anderson RM. The maintenance of strain structure in populations of recombining infectious agents. Nat Med 1996; 2:437-42.
7. Maiden MC. Population genomics: diversity and virulence in the Neisseria. Curr Opin Microbiol 2008; 11:467-71.
8. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011; 378:1962-73.
9. MacNeil JR, Medah I, Koussoube D, et al. Neisseria meningitidis serogroup W, Burkina Faso, 2012. Emerg Infect Dis 2014; 20:394-9.
10. Broker M, Jacobsson S, Kuusi M, et al. Meningococcal serogroup Y emergence in Europe: update 2011. Hum Vaccin Immunother 2012; 8: 1907-11.
11. Broker M, Jacobsson S, DeTora L, Pace D, Taha MK. Increase of meningococcal serogroup Y cases in Europe: a reason for concern? Hum Vaccin Immunother 2012; 8:685-8.
12. Hedberg ST, Toros B, Fredlund H, Olcen P, Molling P. Genetic characterisation of the emerging invasive Neisseria meningitidis serogroup Y in Sweden, 2000 to 2010. Euro Surveill 2011; 16:pii=19885.
13. Buckee CO, Jolley KA, Recker M, et al. Role of selection in the emergence of lineages and the evolution of virulence in Neisseria meningitidis. Proc Natl Acad Sci U S A 2008; 105:15082-7.
14. Caugant DA, Maiden MC. Meningococcal carriage and disease-population biology and evolution. Vaccine 2009; 27(suppl 2):B64-70.
15. Maiden MC. Multilocus sequence typing of bacteria. Annu Rev Microbiol 2006; 60:561-88.
16. Brehony C, Jolley KA, Maiden MC. Multilocus sequence typing for global surveillance of meningococcal disease. FEMS Microbiol Rev 2007; 31:15-26.
17. Harrison LH, Shutt KA, Schmink SE, et al. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era-United States, 2000-2005. J Infect Dis 2010; 201:1208-24.
18. Mothershed EA, Sacchi CT, Whitney AM, et al. Use of real-time PCR to resolve slide agglutination discrepancies in serogroup identification of Neisseria meningitidis. J Clin Microbiol 2004; 42:320-8.
19. Katz LS, Bolen CR, Harcourt BH, et al. Meningococcus genome informatics platform: a system for analyzing multilocus sequence typing data. Nucleic Acids Res 2009; 37:W606-11.
20. Maiden MC, Bygraves JA, Feil E, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 1998; 95: 3140-5.
21. Elias J, Harmsen D, Claus H, Hellenbrand W, Frosch M, Vogel U. Spatiotemporal analysis of invasive meningococcal disease, Germany. Emerg Infect Dis 2006; 12:1689-95.
22. Jolley KA, Brehony C, Maiden MC. Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiol Rev 2007; 31:89-96.
23. DiermayerM, Hedberg K, Hoesly F, et al. Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain. JAMA 1999; 281:1493-7.
24. Russell JE, Urwin R, Gray SJ, Fox AJ, Feavers IM, Maiden MC. Molecular epidemiology of meningococcal disease in England and Wales 1975-1995, before the introduction of serogroup C conjugate vaccines. Microbiology 2008; 154:1170-7.
25. Watkins ER, Maiden MC. Persistence of Hyperinvasive Meningococcal Strain Types during Global Spread as Recorded in the PubMLST Database. PloS One 2012; 7:e45349.
26. Zhou J, Lefebvre B, Deng S, et al. Invasive serogroup B Neisseria meningitidis in Quebec, Canada, 2003 to 2010: persistence of the ST-269 clone since it first emerged in 2003. J Clin Microbiol 2012; 50: 1545-51.
27. Trotter CL, Ramsay ME, Gray S, Fox A, Kaczmarski E. No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England andWales. Lancet Infect Dis 2006; 6:616-7; author reply 7-8.
28. Urwin R, Russell JE, Thompson EA, Holmes EC, Feavers IM, Maiden MC. Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun 2004; 72:5955-62.
29. Wang X, Cohn A, Comanducci M, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine 2011; 29:4739-44.
30. Serruto D, Bottomley MJ, Ram S, Giuliani MM, Rappuoli R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 2012; 30(suppl 2):B87-97.